End Brain Cancer Initiative names Becky Moroney 2026 National HOPE Award recipient

By AI, Created 4:40 PM UTC, May 21, 2026, /AGP/ – The End Brain Cancer Initiative has named glioblastoma patient Becky Moroney as the 2026 National HOPE Award recipient during its annual GBM treatment-options webinar. The award spotlights a patient whose story and advocacy are intended to educate and support the brain cancer community.

Why it matters: - The National HOPE Award spotlights a brain cancer patient whose experience can help other patients and caregivers navigate a difficult diagnosis. - The award is part of EBCI’s disease education work, which aims to improve access to information, specialists, treatments and clinical trials.

What happened: - The End Brain Cancer Initiative announced Becky Moroney as the 2026 recipient of its National HOPE Award during the annual “Know All Your GBM/rGBM Treatment Options” patient education webinar. - Moroney was diagnosed with glioblastoma, an aggressive form of brain cancer, in 2021. - Julie Smith, Moroney’s sister, nominated her for the award.

The details: - EBCI has presented the National HOPE Award every May for more than a decade. - The organization created the patient disease education initiative to highlight people who have inspired others through their brain cancer journey. - EBCI described Moroney as a devoted mother and a source of hope for the glioblastoma community. - Smith said Moroney is “not just surviving but thriving.” - Novocure and other supporters helped make the patient education campaign possible. - Novocure is a global oncology company focused on Tumor Treating Fields therapy. - Novocure’s commercialized products are approved in certain countries for adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. - Novocure has ongoing or completed clinical trials studying Tumor Treating Fields in glioblastoma, non-small cell lung cancer and pancreatic cancer. - Novocure’s headquarters are in Baar, Switzerland, with U.S. headquarters in Portsmouth, New Hampshire, and research and development facilities in Haifa, Israel. - EBCI is a 501(c)(3) nonprofit patient advocacy organization focused on disease education, awareness, outreach, patient access and improving standard of care. - EBCI, formerly known as the Chris Elliott Fund, says all patients diagnosed with brain cancer, a brain tumor or metastatic disease to the brain should have equal access to advanced diagnostics, treatments, specialists and clinical trial participation. - EBCI encourages patients and caregivers to have informed conversations with medical teams. - EBCI asks supporters to consider a $50 donation or more to support its free programs and services at the donation page. - More information about Novocure is available at the company’s website. - More information about EBCI is available at EndBrainCancer.org.

Between the lines: - The award functions as both recognition and outreach, tying an individual patient story to a broader education campaign. - The emphasis on access, diagnostics and clinical trials suggests EBCI is using the award to reinforce its advocacy message, not just to honor one patient.

What’s next: - EBCI is expected to continue its annual HOPE Award program each May. - The organization will also continue fundraising and sponsorship efforts to support future patient education initiatives. - EBCI says donations will help sustain its free programs and services. - Contact information for EBCI’s Dellann Elliott Mydland was provided for additional information.